10x Genomics, Inc. (TXG)

10x Genomics, Inc. attains an AlphaScore of 51/100 in the Healthcare sector as of October 11, 2026. The share price stands at 80.65 with an undefined trailing P/E and a very high forward P/E of 1051.91. Additional data includes a negative return on equity of -5.47 and a gross margin of 69.05. A key strength is the company's healthy gross margin of 69.05 and positive revenue growth of 5.25. The primary risk is the negative net margin of -6.77 and lack of profitability reflected in the negative ROE. Evidence is limited exclusively to the provided metrics.

Written 11/10/2026, 00:43:50 UTC · Snapshot 11/10/2026